Canget Biotekpharma LLC

Buffalo, NY

UEI
TJ1JCE59GKX3
CAGE
6REQ2
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Asian-Pacific American Owned
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
102 Surrey Run, Buffalo, NY 14221, USA
Website
canget-biotek.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Canget Biotekpharma LLC's 3 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient… Grant · R43CA275410 National Cancer Institute $400,000
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma Grant · R43CA221389 National Cancer Institute $224,919
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer Grant · R44CA176937 National Cancer Institute $2,326,369

Quick answers

What is Canget Biotekpharma LLC's UEI?

Canget Biotekpharma LLC's Unique Entity ID (UEI) in SAM.gov is TJ1JCE59GKX3.

What is Canget Biotekpharma LLC's CAGE code?

Canget Biotekpharma LLC's CAGE code is 6REQ2.

Where is Canget Biotekpharma LLC located?

Canget Biotekpharma LLC's physical address in SAM.gov is 102 Surrey Run, Buffalo, NY 14221, USA.

Is Canget Biotekpharma LLC registered in SAM.gov?

Yes. Canget Biotekpharma LLC's SAM.gov registration is active through February 20, 2027.

What is Canget Biotekpharma LLC's most recent federal award?

Canget Biotekpharma LLC's most recent federal grant award is Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient… (R43CA275410), from National Cancer Institute, on September 12, 2023.

On GovTribe

See Canget Biotekpharma LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login